Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Skywatcher who wrote (1414)	1/8/2002 9:53:53 AM
From: Linda Pearson	Respond to of 1477

Scios and GlaxoSmithKline Sign Licensing Agreement for Natrecor in Europe LONDON and SUNNYVALE, Calif., Jan. 7 /PRNewswire/ -- GlaxoSmithKline plc (GSK) and Scios Inc. (Nasdaq: SCIO) today announced that they have entered into an agreement in which Scios will license Natrecor(R) (nesiritide), a treatment for acute heart failure, to GSK in all European markets. Under the terms of the agreement, GSK will have the rights to sell and distribute the product for which Scios will receive an up-front fee and milestone payments over four years, in addition to future royalties on European sales. Scios will manufacture and supply the bulk product to GSK. Both companies will work together to continue clinical development of Natrecor in Europe. In order to obtain European approval for Natrecor, GSK expects to use the extensive clinical data Scios submitted to obtain approval from the U.S. Food and Drug Administration in August 2001. The companies expect to launch Natrecor in Europe in the first half of 2004. Commenting on the agreement, Christopher Viehbacher, President, Pharmaceuticals Europe, GlaxoSmithKline said: "Natrecor adds another important product to our cardiovascular pipeline and complements our existing products, in cardiovascular and emergency medicine in Europe. This agreement is indicative of our intention to become the partner of choice for those companies wishing to maximize the commercial potential of their products and increase their global presence." Richard B. Brewer, Scios' president and chief executive officer, added that "Natrecor will offer physicians in Europe a new alternative for treating acute heart failure, just as it has in the United States. We are excited about the collaboration with GSK, one of the world's pharmaceutical leaders, to further enhance Natrecor's potential value in treating this disease and realizing its blockbuster potential." Natrecor is the first of a new drug class and is a recombinant form of B-type natriuretic peptide (BNP), a hormone secreted by the heart in response to heart failure. Scios launched Natrecor in the United States in August 2001, making it the first new drug available for acute heart failure patients in over a decade. In Europe approximately one million patients are admitted to hospital with a primary diagnosis of acute congestive heart failure each year. JPMorgan H&Q Presentation Details Mr. Brewer will present today at the 20th Annual JPMorgan H&Q Healthcare Conference at 2:00 p.m. PST in the Colonial Room of the Westin St. Francis Hotel in San Francisco, Calif. The presentation will be available via live webcast at www.eventsdigital.com/events/jpmhq/healthcare2002 and archived for 60 days following the presentation or by logging onto the investor section of the company's website at www.sciosinc.com . GlaxoSmithKline GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Scios Inc. Scios is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory disease. The Company's disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally design small molecule compounds for large markets with unmet medical needs. Forward-Looking Safe Harbor Statement This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We generally identify such forward-looking statements using words like "believe," "intend," "expect," "may," "should," "plan," "project," "contemplate," "anticipate" or similar statements. Statements that are not historical facts are forward-looking statements based on current assumptions that involve risks and uncertainties. These risks and uncertainties may include the sales penetration and success of Natrecor, obtaining regulatory approval and market acceptance in Europe, the success of clinical trials of our pipeline products, including SCIO-469, as well as other risks detailed from time to time in the reports filed by Scios with the SEC, including the Company's quarterly reports and annual report on Form 10-K. Actual results, performance or achievements of Scios may differ significantly from those described in these forward-looking statements. Scios disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise. MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com SOURCE Scios Inc. CO: Scios Inc.; GlaxoSmithKline plc ST: California, England IN: BIO MTC SU: LIC CCA 01/07/2002 09:02 EST prnewswire.com

To: Skywatcher who wrote (1414)	1/8/2002 9:55:00 AM
From: Linda Pearson	Read Replies (1) \| Respond to of 1477

Scios Announces Strong Fourth Quarter and Year End Natrecor Sales And Increases 2002 Sales Outlook Scios' 168-Person Sales Force and Marketing Group Successfully Penetrating The Growing Acute Heart Failure Market SUNNYVALE, Calif., Jan. 7 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO) announced today that net sales for its lead product Natrecor(R) (nesiritide) were $9.6 million in the fourth quarter of 2001, its first full quarter of sales. Net sales of Natrecor for the year ended 2001 were $14.1 million, only four and a half months after commercial launch in the United States. Based on this strong start, Scios has raised its full year 2002 net sales outlook for Natrecor to $55 to $60 million. "We are getting great feedback from the increasing number of clinicians using Natrecor around the country. As a result, Natrecor is now stocked in nearly 1,000 hospitals and being added to more and more hospital formularies every month," said Richard B. Brewer, Scios' President and Chief Executive Officer. "Our recently announced partnership with GlaxoSmithKline in Europe will expand the global sales growth potential of Natrecor significantly." "In addition, we continue to roll out ADHERE, our national Acute Decompensated HEeart failure REgistry, and study Natrecor in additional heart failure treatment settings. Successful implementation of these programs in addition to core market penetration in the United States and Europe should enable Natrecor to achieve top-tier sales levels over the next five years." Natrecor is the first of a new drug class and a recombinant form of B-type natriuretic peptide (BNP), a naturally occurring hormone secreted by the heart in response to heart failure. The initial promotional focus has been with cardiology and emergency medicine physicians. Scios has seen considerable usage and frequent reorders in its targeted hospitals. Acceptance of Natrecor has also been indicated by a high level of interest by national Group Purchasing Organizations (GPOs) and managed care. Several contracts have been completed and additional contracts are in the final stages with several GPOs. Natrecor was also recently added to the Kaiser formulary in both Northern and Southern California. "Our sales results confirm that Natrecor fills a growing market need," said Thomas Feldman, Scios' Vice President of Sales and Marketing. "Our understanding of the market allowed us to penetrate initial targets quickly and effectively. This, coupled with our strong sales force, makes us very optimistic about achieving sales goals in 2002 and beyond." Presentation / Webcast Details at JP Morgan H & Q Mr. Brewer will present at the 20th Annual JPMorgan H&Q Healthcare Conference at 2:00 p.m. PST in the Colonial Room of the Westin St. Francis Hotel in San Francisco, Calif. The presentation will be available via live webcast at www.eventsdigital.com/events/jpmhq/healthcare2002 and archived for 60 days following the presentation or by logging onto the investor section of the company's website at www.sciosinc.com. Fourth Quarter and Year End Conference Call Details The company will discuss additional details when it releases fourth quarter and full year 2001 financial results on Thursday, February 7, 2002. The customary quarterly conference call will be held at 7:00 a.m. PT / 10:00 a.m. ET. The call will also be broadcast live and archived on Scios' web site at www.sciosinc.com. Scios Inc. Scios is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory disease. The Company's disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally design small molecule compounds for large markets with unmet medical needs. Forward-Looking Safe Harbor Statement This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We generally identify such forward-looking statements using words like "believe," "intend," "expect," "may," "should," "plan," "project," "contemplate," "anticipate" or similar statements. Statements that are not historical facts are forward-looking statements based on current assumptions that involve risks and uncertainties. These risks and uncertainties may include the sales penetration and success of Natrecor, the success of clinical trials of Natrecor and our pipeline products, including SCIO-469, as well as other risks detailed from time to time in the reports filed by Scios with the SEC, including the Company's quarterly reports and annual report on Form 10-K. Actual results, performance or achievements of Scios may differ significantly from those described in these forward-looking statements. Scios disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise. MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com SOURCE Scios Inc. CO: Scios Inc. ST: California IN: BIO MTC SU: ERP CCA 01/07/2002 16:15 EST prnewswire.com